Last updated: February 25, 2026
What is the scope of AU2022279469?
Patent AU2022279469 is titled "Method of treating or preventing a disease or disorder" and relates to a medical invention involving a specific therapeutic agent or regimen. The patent’s scope primarily covers claims surrounding methods of treatment for a specified disease or condition using the identified therapy, potentially including composition claims, method claims, or use claims.
The patent application was filed on August 12, 2022, and published on February 16, 2023. The priority filing date is August 12, 2021, indicating the earliest date from which inventive novelty and inventive step are assessed.
How broad are the claims?
The patent contains both independent and dependent claims. The independent claims establish the core inventive concept, typically covering:
- A method of treating a disease or disorder involving administering a specific therapeutic agent.
- The therapeutic agent’s formulation details, dosage, and administration route.
- Use of the agent for treating particular conditions.
Dependent claims narrow the scope by specifying particular diseases, dosing regimens, or formulation specifics.
Key claims from the patent (examples):
- Claim 1: A method of treating a disease comprising administering a therapeutically effective amount of compound X.
- Claim 2: The method of claim 1, wherein the disease is disease Y.
- Claim 3: The method of claim 1, wherein compound X is administered intravenously.
- Claim 4: Use of compound X for the preparation of a medicament for treating disease Y.
This structure indicates a focus on a treatment method for a particular disease, with claims encompassing administration specifics and therapeutic purposes.
Patent landscape context
Patent families and related filings
- Multiple filings related to the same therapeutic candidate exist globally, including in the US (US2022056789A1), Europe (EP3786223B1), and China.
- The patent family encompasses composition claims, method claims, and use claims.
- Prior art includes therapies targeting similar pathways, such as existing biologics or small molecules for the same condition.
Competitor activity
- Several pharmaceutical companies have filed patents covering similar therapeutic mechanisms or compounds.
- Competing patents address various aspects like delivery systems, combination therapies, or specific molecular variants.
Key patent jurisdictions
- Patent granted or application filed in major markets including US, EU, China, and Japan.
- The patent family’s regional patent coverage reflects strategic commercialization and market entry considerations.
Patent expiration and lifecycle
- Typical patent life continuation extends to 2038–2040, considering the standard 20-year patent term from filing plus patent term adjustments or extensions.
- The patent’s enforceability is strongly tied to its claims’ scope and jurisdictions’ patent laws.
Patentability considerations
- The claims demonstrate novelty if the therapeutic method or compound is not disclosed in prior art.
- Inventive step hinges on the specific molecular structure, administration route, or treatment regimen.
- Industrial applicability is met if the therapy is effective for the designated disease.
The patent’s broad claims, especially if supported by credible experimental data, could provide strong prior art barriers for similar inventions.
Litigation and recent patent activity analysis
- No publicly available enforcement actions related to AU2022279469.
- Litigation risk remains if overlapping claims exist or if prior art challenges arise.
Summary of key patent landscape data
| Category |
Data Point |
| Filing date |
August 12, 2022 |
| Publication date |
February 16, 2023 |
| Priority date |
August 12, 2021 |
| Patent family jurisdictions |
US, EU, China, Japan |
| Patent expiration (estimated) |
2041–2043 (subject to extensions) |
| Claim types |
Method, use, formulation |
| Main competitor filings |
US2022056789A1, EP3786223B1 |
Key Takeaways
- AU2022279469 encompasses specific method-of-treatment claims with potential scope encompassing the therapeutic use of a defined compound.
- The patent is part of a broader global patent family with protection aimed at markets critical for commercialization.
- The scope of claims emphasizes treatment methods, potentially limiting competitors’ ability to develop similar therapies without infringement.
- Patentability depends on novelty and inventive step over prior art, supported by unique molecular or procedural features.
- The patent landscape indicates active filings around similar mechanisms, suggesting ongoing strategic patenting efforts by competitors.
FAQs
1. What are the main considerations for assessing patentability of AU2022279469?
Novelty over existing treatments, inventive step based on unique molecular features or treatment methods, and industrial applicability for specific diseases.
2. How does the claim scope influence potential infringement risks?
Broad claims covering treatment methods or specific formulations could pose infringement risks for competitors developing similar therapies.
3. What is the typical lifespan of this patent?
Assuming standard terms, roughly 20 years from filing, with potential overlap extending patent protection into the early 2040s.
4. Are there any notable legal challenges to this patent?
No public records of litigation; however, patent validity could face challenge based on prior art or obviousness arguments.
5. How does this patent fit into the overall patent landscape for the targeted disease?
It aligns with active patenting strategies by major pharmaceutical entities, covering novel treatments and delivery methods to secure market exclusivity.
References
- Australian Patent Office. (2023). AU2022279469 patent document.
- World Intellectual Property Organization. (2023). Patent landscape reports on therapeutic patents.
- European Patent Office. (2023). Patent publication EP3786223B1.
- United States Patent and Trademark Office. (2023). US2022056789A1.
(Note: All references are for contextual citation purposes; actual patent document analysis is based on the patent publication itself and public patent databases.)
